SCHEMBL22001607

SCHEMBL22001607

CC(C)P(=O)(OCC(C)(C)C)N1CCN(c2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.41
TSHR P16473 2/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 4/20 0.40
GLA P06280 1/20 0.40
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CHRNA7 P36544 1/20 0.40
NPSR1 Q6W5P4 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DRD2 P14416 2/20 0.38
DRD4 P21917 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
GAA P10253 1/20 0.36
RECQL P46063 1/20 0.36
LMNA P02545 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408773 0.82 TSHR (0.42) GFERTSHRALDH1A1KDM4EL3MBTL1
SCHEMBL22001600 0.80 LMNA (0.42) ALDH1A1KDM4EMAPTTDP1SMN1; SMN2
SCHEMBL23347868 0.76
SCHEMBL21316728 0.75 MEN1 (0.45) ALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL22000950 0.75 HRH3 (0.31) SIGMAR1
SCHEMBL23347870 0.74 MEN1 (0.44) TSHRMAPTSMN1; SMN2GAA
SCHEMBL22001603 0.74 KDM4E (0.32) ALDH1A1KDM4E
SCHEMBL22001232 0.73 NPSR1 (0.51) TSHRALDH1A1NPSR1CHRM1
SCHEMBL22001601 0.72 SIGMAR1 (0.30) SIGMAR1
SCHEMBL23347876 0.71 MEN1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11071749-B2 Oligonucleotide analogues targeting human LMNA SAREPTA THERAPEUTICS, INC. (US) 2021-07-27 US disclosed
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. 2021-05-13 US disclosed
US-20200147119-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11071749-B2 Oligonucleotide analogues targeting human LMNA LMNB2, LMNA, LMNB1 GFER 4336/4885TSHR 1863/4885ALDH1A1 4394/4885
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB GFER 2202/4885TSHR 2993/4885ALDH1A1 2803/4885
US-20200147119-A1 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA LMNB2, LMNA, LMNB1 GFER 4336/4885TSHR 1863/4885ALDH1A1 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.